Supernus Pharmaceuticals, Inc. · NASDAQ:SUPN
Supernus Pharmaceuticals — Merger or Acquisition (August 2026)
13 slides from Supernus Pharmaceuticals's merger presentation, Aug 3, 2026
Slide 1: Merger of Equals to Create a Diversified CNS Biopharmaceutical Leader with Significant Scale
Merger of Equals to Create a Diversified CNS Biopharmaceutical Leader with Significant Scale AUGUST 3, 2026
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation, and any related oral statements made by representatives of Supernus or Indivior in connection with it, contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. F
Slide 3: Additional Information
Additional Information 3 NO OFFER OR SOLICITATION This communication is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy or exchange any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in
Slide 4: Today's Presenters
Today's Presenters Jack Khattar President and Chief Executive Officer Supernus Pharmaceuticals Joe Ciaffoni Chief Executive Officer Indivior Pharmaceuticals Tim Dec Senior Vice President, Chief Financial Officer Supernus Pharmaceuticals 4
Slide 5: Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale Creates a CNS leader through the combination of two highly complementary businesses Combines two differentiated commercial portfolios, creating a portfolio of 11 medicines with key growth products currently expected to contin
Slide 6: Transaction Summary
Transaction Summary TRANSACTION STRUCTURE • 100% tax-free stock-for-stock merger • Supernus shareholders to receive 1.5401 Indivior shares for each Supernus share CASH DISTRIBUTION TO INDIVIOR SHAREHOLDERS • Prior to closing, Indivior will declare a dividend of $1B in the aggregate to pre-closing st
Slide 7: Combination Creates CNS Leader with a ~$2.2Bn Diversified Portfolio of Commercial Assets
(Epilepsy and Prophylaxis of Migraine) Combination Creates CNS Leader with a ~$2.2Bn⁽¹⁾ Diversified Portfolio of Commercial Assets G ADDICTION / USE DISORDERS PSYCHIATRY NEUROLOGY COMBINED COMPANY NET REVENUE LTM as of 6/30/26 $2,162 million INDIVIOR Total Sublocade $956 Suboxone Film (US) $227 Ex-U
Slide 8: Ideal Time to Build on Supernus and Indivior Strategic Progress
Ideal Time to Build on Supernus and Indivior Strategic Progress Supernus Indivior STRATEGIC FOCUS • Expanding portfolio through growth of current commercial portfolio, business development, and advancement of mid- to late-stage innovative CNS pipeline • Successful track record of acquiring and integ
Slide 9: Supernus CNS Pipeline to Drive Potential Long-Term Growth
Supernus CNS Pipeline to Drive Potential Long-Term Growth PROGRAM INDICATION DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 FILING SPN-817 Epilepsy SPN-820 Depression SPN-443 ADHD Discovery CNS Wholly-owned CNS pipeline provides optionality beyond the commercial portfolio Note: Bar extent reflects th
Slide 10: Pro Forma Key Financial Metrics
Pro Forma Key Financial Metrics LTM as of 6/30/26⁽¹⁾ · $ in millions $2,162m Total net revenue $888m Adjusted EBITDA⁽²⁾ 41% Adjusted EBITDA margin⁽²⁾ <1x Net leverage⁽⁴⁾ Supernus Indivior PRO FORMA COMBINED COMPANY Total Net Revenue $830 $1,332 $2,162 Adjusted EBITDA $150 $613 $888⁽²⁾ Adjusted EBITD
Slide 11: Value Creating Transaction
Value Creating Transaction Builds a diversified CNS biopharmaceutical leader with significant scale Enhances and diversifies growth profile Differentiated portfolio with key growth products expected to continue growing well into the 2030s Four key commercial therapeutic areas Increased scale and imm
Slide 12: Accelerated Profitability and Cash Flow Generation Drives Greater Financial Flexibility
Accelerated Profitability and Cash Flow Generation Drives Greater Financial Flexibility Drive growth in commercial portfolio Invest behind SUBLOCADE, Qelbree, ZURZUVAE, ONAPGO and GOCOVRI Advance development pipeline Fund mid- to late-stage CNS programs through value-creating milestones Pursue futur
Slide 13: Q&A
@Supernus’ | SINDIVIOR Pharmaceuticals Q&A
Supernus Pharmaceuticals — Merger or Acquisition (August 2026) on 6ix